

Minutes of the meeting with Johnson&Johnson of 18 March 2021

Present:

Johnson&Johnson:



TFIS

- Hubert



Update on the sites provided by J&J:

- It is foreseen that IDT in Germany would be up and running in May and June.
- J&J confirmed that it expanded the cooperation with Catalent so that it will have a second production line. Therefore, J&J is hopeful to meet its commitment of 55million doses for Q2. And for Q3 J&J it is comfortable to meet the delivery targets.
- Catalent site will be available to J&J as of 1 April, J&J is doing all it can to gain time by obtaining waivers and exemptions.
- By next week, J&J should know whether and which bottlenecks there still are for the Catalent site. J&J will send us a list

Export:

- J&J pointed out that it had been in contact with the head of cabinet of our Commissioner and of the President, with regard to the export of Inoculum and seed (there is more than enough of these substance in the EU) which is an intermediate product, needed for EU. Whilst the capacity of the Leiden production site is being doubled, production had to be done in US, as there is no other site available right now. J&J said that they had been insured by the US that there would be no problem to export the drug substance from the US.
- The head of the TFIS pointed out that it had been informed by the Italian Government about five possible additional production sites. The TFIS will send list to J&J.

Delivery targets for Q2:

- Next week J&J should be able to provide for each production site the expected capacity, at least for April and May.

Feedback on list of critical materials and disposables for the IDT site

- The TFIS gave some feedback on J&J's list of critical materials and disposables for the IDT site. With the exception of two items, all could be delivered. For the two issues it had to be checked whether the alternative solution offered by IDT would work. J&J will get in contact with IDT.